Mild Coccidioidomycosis at Nine Weeks — Treating the Fetus's Risk Against the Drug's
A single patient, nine weeks pregnant with disease mild enough that most patients wouldn't be treated at all. The disagreement is whether pregnancy alone should change that answer, and whether the standard drug is even a safe way to find out.
C.V., a 29-year-old woman, moved to Bakersfield eight weeks ago for a new job selling agricultural equipment, and confirmed she was pregnant — her first, after several years of trying — the same week the dry cough that had been nagging her for a few days turned into something she couldn't shake. She is previously healthy, with no other medical history. Three weeks of persistent cough and fatigue brought her to urgent care, where a faint, tender rash on both shins caught the physician's attention alongside the respiratory symptoms; a chest CT showed a single peripheral pulmonary nodule, and coccidioidal serology came back positive by EIA, confirmed on immunodiffusion. She is now 9 weeks pregnant, with mild disease by every objective measure — no hypoxia, a single nodule rather than diffuse involvement, and vital signs that have stayed entirely normal through three weeks of symptoms.
Coccidioidomycosis in an immunocompetent, non-pregnant adult with disease this mild is often managed with observation alone, since the large majority of cases resolve without antifungal therapy. Pregnancy has long been named as a risk factor for dissemination, but the foundational literature behind that association — Smale and Waechter's series, and Peterson's later review of coccidioidomycosis in pregnancy — concentrates heavily in the third trimester and the immediate postpartum period, a very different point in gestation than her current nine weeks. Galgiani's IDSA coccidioidomycosis guideline reflects exactly that split, recommending amphotericin B rather than an azole when treatment is needed in the first trimester. Fluconazole carries the embryopathy pattern Pursley first described — craniofacial and skeletal malformations after prolonged, higher-dose first-trimester exposure of the kind her weeks-to-months course would require, not the single 150mg dose used for vaginal candidiasis that much of the reassuring pregnancy safety data actually describes. Her own coccidioidal titer, checked at a moderate rather than high level, is itself a variable the group is still weighing against a risk-factor literature that wasn't built around a case exactly like hers.
In clinic, weighing two risks that don't share a unit
Pregnancy is a real, historically described dissemination risk factor for coccidioidomycosis — Smale and Waechter put it on the map and Peterson's review kept it there — and disseminated disease in pregnancy has been catastrophic in the case reports describing it. I'd rather treat now with amphotericin B, which doesn't carry fluconazole's teratogenicity profile, than watch and hope the dissemination literature doesn't apply to her.
I take the dissemination concern seriously, but the literature behind it is concentrated in the third trimester and immediate postpartum — she's at nine weeks, a genuinely different point in gestation than most of those case reports describe. And amphotericin B isn't risk-free in pregnancy either; Galgiani's guideline prefers it in the first trimester on the teratogenicity axis specifically, but that is a statement about which drug to use if you treat, not an argument that she needs treating.
Citing the pregnancy-dissemination association without naming which trimester it was actually observed in overstates how much it applies to her specific timing.
Her own numbers matter more here than the general association. Her titer is moderate, not the high level that's historically flagged higher dissemination risk, and she has no other named risk factor stacking on top of the pregnancy itself. In a non-pregnant patient with this exact presentation, we'd observe. I'd propose close observation with serial coccidioidal titers and monthly follow-up, with an explicit, low threshold to start therapy if the titer rises or she moves into the third trimester — where I'd agree the calculus genuinely shifts.
Agreed: close observation with serial coccidioidal titers and monthly combined OB/ID follow-up, given her mild disease, moderate titer, and absence of additional dissemination risk factors, with an explicit plan to start amphotericin B immediately if her titer rises, new symptoms suggest dissemination, or she reaches the third trimester.
Not agreed: the ID physician's underlying discomfort with observation itself is documented as unresolved, not talked out of — he supported the plan given the specific numbers in front of him today, but stated plainly that his threshold for reversing course is lower than the other two specialists', and asked that any ambiguous finding at follow-up be brought back to the full group rather than decided unilaterally.